Taconic Biosciences’ Post

Exciting news! We've identified 36c with a (thiophen-3-yl)aminopyrimidine scaffold as a potent ERK1/2 inhibitor through structure-guided optimization. The RAS-RAF-MEK-ERK signaling cascade is abnormally activated in various tumors and plays a crucial role in tumor progression. As the key component at the terminal stage, ERK1/2 emerges as a potential antitumor target. In preclinical studies, 36c showed powerful inhibitory activities and potent antitumor efficacy against triple-negative breast cancer and colorectal cancer models harboring BRAF and RAS mutations. It can directly inhibit ERK1/2, block the phosphorylation expression of downstream substrates, and induce cell apoptosis and incomplete autophagy-related cell death. This work has been published in J Med Chem. Looking forward to more progress in the future! 🎉#ERK1/2 inhibitor #J Med Chem #tumor treatment #drug discovery #RAS-RAF-MEK-ERK  #preclinical  #autophagy-related cell death  #medicinal chemistry https://lnkd.in/ejvfZBAu

🔬 Excited to present our latest scientific developments in Alzheimer’s disease (AD) at the #ADPD2024 Conference! 💡   “The small molecule GAL-201 belongs to a new pharmacological class of amyloid beta aggregation modulators that acts upstream of other known Aβ-targeting agents in Alzheimer’s disease,” explained Hermann Russ, M.D. Ph.D. founder, and Chief Scientific Officer of Galimedix Therapeutics, Inc. “The positive preclinical results presented at AD/PD™ 2024 demonstrate how treatment with GAL-201 has a potential neuroprotective effect and may also improve cognitive function.”   These results further support that toxic Aβ oligomers and protofibrils are a major underlying cause of this devastating disease. We look forward to advancing this promising new drug candidate in development. 💊 Read more here: https://lnkd.in/dtqgVZSN #AlzheimersDisease #GAL201 #LifeScience

Don't get stuck trying to use a nuclease that 'gets close' to where you want to edit in the genome because there is not a PAM sequence close by - close is not good enough. Use a nuclease that provides you the flexibility you need to edit your desired gene target. One of the many benefits of Synthego Corporation's hfCas12Max is its broad PAM sequence recognition profile, which enables gene editing in locations previously deemed uneditable using current nuclease options. Casey Jowdy does a great, easy-to-follow walkthrough about hfCas12Max and its abilities in a variety of gene editing applications. #CRISPR

Can ctDNA predict outcomes in early phase trials?  Two studies presented at #ESMOTAT24 suggest that circulating tumour (ct)DNA could be a useful tumour-agnostic biomarker that may expedite the assessment of new therapeutics.  In an #ESMODailyReporter article, Christian Rolfo, MD, PhD, MBA,Dr.h.c. comments that ctDNA analysis is non-invasive, rapid and relatively inexpensive, and results from studies further open up its potential to be more widely applied in early phase #ClinicalTrials. 👉Read the full article here https://ow.ly/eTfU50QIha5

Check out our blog post on the crucial role of assessing cell health from lab bench to beside. You’ll also learn more about our Cell Health Portfolio for viability, toxicity, and proliferation assessments, empowering cell therapy developers to craft breakthrough therapeutics. #celltherapy #biotechnology #analyticaldevelopment #NoControlsNoConfidence 🧬 https://lnkd.in/ei-GMwR7

Protein Tracking: Everything, everywhere, almost at once A new platform that can follow the movement of individual proteins inside millions of cells in a single day will help contribute to existing knowledge of cell biology and identify new therapeutics. https://lnkd.in/edUjHinH

Curious about how biological, technological, manufacturing, and clinical considerations come together to create a product? Or what critical factors need to be considered when mapping out a strategic pathway and mitigating risks in the development of gene-based cell therapeutics for human use? Read more in the research article co-authored by Kristina Carroll, "Selecting a Cell Engineering Methodology During Cell Therapy Product Development." #mbse #systemsengineering #catia #modeling #dassault #MBSEtraining #systemsthinking #incose #celltherapy #biotechinnovation INCOSE

TLK2 presents a promising opportunity for drug development in various cancer types, yet the lack of potent and selective TLK2 inhibitors as chemical probes has hindered the investigation of TLK2 biology. Researchers conducted a comprehensive approach to optimize a chemotype for increased potency and selectivity, culminating in the development of the inhibitor UNC-CA2-103. Learn more: https://lnkd.in/g24d8Rwy

We are focused on developing novel therapeutics for the treatment of neuronal hypersensitivity disorders. https://bit.ly/3ZQ0Qmu #chroniccough #neuropathicpain #migraine #hyperactivebladder

How can you ensure your FMT assay is as efficient as possible? Our innovative Fibroblast-to-Myofibroblast Transition (FMT) Assay allows high-throughput in vitro evaluation of anti-fibrotic therapeutics. 🔸 Tissue type: Newcells uses primary human lung fibroblasts for their FMT assay 🔸 Assay Window: The assay window spans 72 hours 🔸 Optimized culture conditions that promotes mature collagen fibril deposition in the extracellular compartment 🔸 Analytical Readouts: Quantification of collagen I expression, αSMA expression, cell proliferation rates, and more Discover how to use our primary lung fibroblast model here: https://lnkd.in/gx65ZMWN #NewcellsBiotech #Lung #BiotechInnovation #Therapeutics